AlloVir downgraded by Leerink Partners
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Leerink Partners downgraded AlloVir from Outperform to Market Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/26/2023 | $17.00 → $1.00 | Buy → Underperform | BofA Securities |
| 12/22/2023 | Outperform → Market Perform | Leerink Partners | |
| 12/22/2023 | Overweight → Underweight | JP Morgan | |
| 12/22/2023 | Overweight → Neutral | Piper Sandler | |
| 8/18/2023 | $17.00 | Buy | BofA Securities |
| 2/10/2022 | $32.00 → $30.00 | Outperform | SVB Leerink |
| 1/18/2022 | $48.00 → $45.00 | Overweight | Morgan Stanley |
| 12/17/2021 | $37.00 → $32.00 | Outperform | SVB Leerink |